News


All series


All News

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, L. Wayne Keiser, MD, talked about the treatment considerations and decisions he makes when treating patients with colorectal cancer. Keiser, a medical oncologist at St. Joseph Health Medical Group, Santa Rosa, California, explained his treatment decisions for the based on a case scenario of a patient with <em>KRAS</em>-mutated metastatic CRC.

The combination of venetoclax with rituximab led to high rates of undetectable minimal residual disease for patients with relapsed/refractory chronic lymphoblastic leukemia. This was associated with a prolonged progression-free survival, according to a new analysis of a randomized trial presented at the 2018 ASH Annual Meeting.

Danny Rischin, MD, MBBS,&nbsp;discusses the phase II activity with cemiplimab as a novel PD-1 inhibitor for patients with metastatic and locally advanced CSCC.

The PD-1 inhibitor cemiplimab in combination with radiotherapy, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor did not demonstrate efficacy superior to other PD-1 inhibitor monotherapies in patients with recurrent or metastatic head and neck squamous cell carcinoma, according to results from a phase I expansion cohort that were presented at the 2018 ESMO Congress.

Long-term follow-up of patients with relapsed or refractory mantle cell lymphoma treated with venetoclax monotherapy indicate that remissions are durable in a meaningful proportion and that late-onset toxicities are uncommon.

The BTK inhibitor acalabrutinib demonstrated promising reponse rates in patients with&nbsp;newly diagnosed or relapsed/refractory chronic lymphocytic leukemia, according to results from an&nbsp;open-label phase II trial.

The Association of Community Cancer Centers is pleased to announce the hiring of Leigh M. Boehmer, PharmD, BCOP, as Medical Director, Education, for the association&rsquo;s expanding education initiatives. In this role Dr. Boehmer will be responsible for assessing educational needs and designing educational interventions for multidisciplinary cancer care teams serving patients in the community setting.

Patients with advanced basal cell carcinoma who experience progression on hedgehog pathway inhibitor therapy, or are intolerant to it, have no approved therapeutic options. An ongoing phase II study evaluating cemiplimab in this population may prove efficacious based on its activity in other advanced malignancies.

Combination therapy with acalabrutinib plus bendamustine and rituxumab showed an overall response rate in excess of 90% of patients with treatment-na&iuml;ve mantle cell lymphoma and an ORR of 85% in patients with relapsed/refractory disease in an ongoing open-label phase Ib study.<sup>&nbsp;</sup>The safety profile was consistent with expected safety profiles for acalabrutinib and BR, said Tycel Phillips, MD, who presented the data at the 2018 American Society of Hematology Annual Meeting.

During a recent&nbsp;<em>Targeted Oncology&nbsp;</em>case-based peer perspective presentation, William G. Wierda, MD, PhD, revealed the treatment options and decisions he makes when treating patients with chronic lymphocytic leukemia. Wierda explained his treatment decisions based on a patient&rsquo;s case scenario.

AstraZeneca has reported that the&nbsp;phase III EAGLE trial has missed its primary endpoint, as patients with&nbsp;recurrent or metastatic head and neck squamous cell carcinoma who progressed after platinum-based chemotherapy did not see a survival benefit with durvalumab alone or combined with&nbsp;tremelimumab.

The phase III TAHOE trial evaluating rovalpituzumab tesirine as a second-line treatment for&nbsp;patients with advanced small cell lung cancer has been put on hold, based on a recommendation from an&nbsp;Independent Data Monitoring Committee, according to AbbVie, the developer of the investigational antibody-drug conjugate.<br /> &nbsp;

During a <em>Targeted Oncology</em>&nbsp;live case-based peer perspectives presentation, David O&rsquo;Malley, reviewed the treatment considerations and decisions he makes when treating patients with ovarian cancer. O&rsquo;Malley explained to the group the factors that go into treatment decision making during the meeting based on a case scenario of a patient with high-grade serous carcinoma.

Atezolizumab (Tecentriq) has been approved by the FDA&nbsp;for use in combination with bevacizumab, carboplatin, and paclitaxel as a first-line treatment for patients with metastatic nonsquamous non-small cell lung cancer. This indication excludes patients with <em>EGFR</em>/<em>ALK</em> aberrations.

According to findings from the phase III ECHELON-2 trial presented at the 2018 ASH Annual Meeting, the use of brentuximab vedotin (Adcetris) in combination with chemotherapy demonstrated a clinically meaningful improvement in progression-free survival and overall survival in patients with CD30-expressing peripheral T-cell lymphoma. These data were also published online in&nbsp;<em>Lancet Oncology</em>.

Venetoclax monotherapy induced high rates of minimal residual disease in the peripheral blood and bone marrow in patients with&nbsp;relapsed/refractory chronic lymphoblastic leukemia in a pooled analysis of 2 clinical trials. Data from the analysis was reported during the poster session at the 2018 ASH Annual Meeting.

Two-year findings from the ZUMA-1 trial showed an overall survival rate of more than 50% from treatment with&nbsp;axicabtagene ciloleucel, a CD19-targeted CAR T-cell therapy&nbsp;in patients with&nbsp;refractory large B cell lymphoma; the median survival had not yet been reached. These data, representing a clear plateau in the survival curve, were presented at the 2018 ASH Annual Meeting.